Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

A Study of ETHIZIA Versus SURGICEL Original in Controlling Soft Tissue Bleeding During Open Surgery

NCT06664788 · View on ClinicalTrials.gov ↗

Study Summary

The objective of this clinical investigation is to evaluate the safety and efficacy of ETHIZIA to control minimal, mild, or moderate soft tissue bleeding during open surgery when compared to SURGICEL Original in the percentage of cases achieving hemostasis at 3 minutes after product application, and without re-bleeding up to 10 minutes after application.

Interventions

  • DEVICE ETHIZIA
  • DEVICE SURGICEL Original

Study Locations (8)

Other

  • UMC Radboud — Nijmegen
  • UMC Radboud — Nijmegen

California

  • Keck Hospital of USC — Los Angeles

Missouri

  • Washington University Barnes Jewish Hospital — St Louis

New Jersey

  • Capital Health Medical Center - Hopewell — Pennington

New York

  • New York Presbyterian - Weill Cornell Medical Ctr — New York

Texas

  • UT Health East Texas EMS Air 1 — Tyler

Utah

  • Intermountain Medical Center — Murray

Trial Details

FieldValue
Enrollment Target 108 participants
Start Date 2025-04-16
Est. Completion 2026-04-30
Phase NA

Sponsor

Ethicon

37 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06664788

The ClinicalTrials.gov registry entry for NCT06664788 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ethicon, which has 37 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Hemostasis appearing as the primary indexed condition, and to 2 interventions — of which ETHIZIA is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06664788 reports 8 study locations spanning 7 distinct geographic areas — top geographies include Other, California, Missouri. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06664788 about?

NCT06664788 is a clinical study titled "A Study of ETHIZIA Versus SURGICEL Original in Controlling Soft Tissue Bleeding During Open Surgery". The objective of this clinical investigation is to evaluate the safety and efficacy of ETHIZIA to control minimal, mild, or moderate soft tissue bleeding during open surgery when compared to SURGICEL Original in the percentage of cases achieving hemostasis at 3 minutes after product application, and...

What is the current status of trial NCT06664788?

This trial is currently recruiting. It is a NA study. The enrollment target is 108 participants. The study started on 2025-04-16. Estimated completion is 2026-04-30.

What conditions does trial NCT06664788 study?

This clinical trial studies the following conditions: Hemostasis, Hemostatic Techniques. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06664788?

The interventions under investigation include: ETHIZIA (DEVICE), SURGICEL Original (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06664788?

This trial is sponsored by Ethicon, which has 37 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06664788 being conducted?

This trial has 8 study locations across California, Missouri, New Jersey, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial